Reuters logo
8 months ago
BRIEF-Contravir expands Phase 2A trial of tenofovir exalidex to include doses above 100 mg
December 19, 2016 / 11:30 AM / 8 months ago

BRIEF-Contravir expands Phase 2A trial of tenofovir exalidex to include doses above 100 mg

Dec 19 (Reuters) - Contravir Pharmaceuticals Inc

* Contravir Pharmaceuticals - plans to begin evaluating TXL at 150 mg per day dosing and potentially higher dosing based on TXL's performance

* Contravir expands Phase 2A trial of tenofovir exalidex (formerly CMX157) to include doses above 100 mg Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below